KPV is a short alpha-MSH fragment studied for anti-inflammatory effects. It is claimed to improve irritated skin and gut symptoms.
What KPV does and why that matters
KPV is a three-amino-acid fragment of alpha-MSH. In cell and animal studies it has turned down some of the chemical signals that drive inflammation. If that carried over to people, the hoped-for result would be less redness, swelling or irritation in the skin or gut. Human studies have not shown that oral, topical or injected KPV delivers those benefits. [1,2,3]
Function evidence: Cell and animal inflammation findings; human benefit unproven
What an anti-inflammatory effect would mean
For someone with irritated skin or bowel symptoms, a meaningful benefit would be less redness, swelling, discomfort, urgency or disruption to daily life. KPV has reduced selected inflammation signals in cells and experimental colitis in mice, which gives researchers a reason to study those questions. It has not shown those symptom improvements in controlled human trials. The existing work also does not tell us whether an oral, topical or injected product reaches the relevant tissue or whether one route can be substituted for another. [1,2,3]
What supports this description: Cell and mouse inflammation models; patient symptoms not studied
KPV Dosing status
Dose: No consumer dose is established or recommended here. | Frequency: No routine treatment schedule established. | Cycle: No validated consumer cycle. | Route: No routine patient route established.
Preparation: No patient reconstitution recipe. Trial preparation is not a recommendation..
KPV is a three-amino-acid fragment of alpha-MSH. So far, the studies cited here involve cells and animals. They cannot tell us whether oral, topical or injected KPV treats inflammatory bowel disease, skin disease or systemic inflammation in people. [1,2,3]
KPV Effects
Inflammation models. Cell and mouse studies report changes in inflammatory signaling and experimental colitis. They are preclinical results, not demonstrated human symptom relief. [1,2]
KPV Side Effects
Human dosing and safety unknown. No adequate human pharmacokinetic, efficacy, dose-finding, or long-term safety evidence establishes a routine route or regimen. FDA flags limited safety information and peptide-related quality concerns. [3]
Frequently Asked Questions About KPV
Does KPV treat IBD in people?
Not established. The cited work is in cells and animal models, not controlled human IBD trials. [1,2]
Can oral and injectable KPV be treated as equivalent?
No. Route-specific absorption, dose, and safety have not been established in adequate human studies. [1,2,3]
Evidence
Preclinical evidence only for claimed uses. KPV is a three-amino-acid fragment of alpha-MSH. So far, the studies cited here involve cells and animals. They cannot tell us whether oral, topical or injected KPV treats inflammatory bowel disease, skin disease or systemic inflammation in people. [1,2,3]
Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models Inflamm Bowel Dis, 2008. PMID 18092346
Dalmasso G, et al. The alpha-MSH-derived tripeptide KPV decreases intestinal inflammation Gastroenterology, 2008. PMID 18061177
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: KPV , . Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
